Background While our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability, the question remains whether this benefit would outweigh the additional cost of thermostable formulations. Methods Using HERMES simulation models of the vaccine supply chains for the Republic of Benin, the state of Bihar (India), and Niger, we simulated replacing different existing vaccines with thermostable formulations and determined the resulting clinical and economic impact.
Principles of Gender-Specific Medicine (Third Edition), Academic Press, 2017, Pages 183-201.
Principles of Gender-Specific Medicine (Third Edition), Academic Press, 2017, Pages 203-217.